Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.

Ghia P, Rawstron A.

Leukemia. 2018 Jun;32(6):1307-1316. doi: 10.1038/s41375-018-0109-x. Epub 2018 Mar 26.

PMID:
29700386
2.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E.

Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17.

3.

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.

Collett L, Howard DR, Munir T, McParland L, Oughton JB, Rawstron AC, Hockaday A, Dimbleby C, Phillips D, McMahon K, Hulme C, Allsup D, Bloor A, Hillmen P.

Trials. 2017 Aug 22;18(1):387. doi: 10.1186/s13063-017-2138-6.

4.

Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia.

Varghese AM, Rawstron A, Newton D, Tooze RM, Munir T, Dickson M, Doody GM, Hillmen P.

Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14884. [Epub ahead of print] No abstract available.

PMID:
28770560
5.

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial.

Oughton JB, Collett L, Howard DR, Hockaday A, Munir T, McMahon K, McParland L, Dimbleby C, Phillips D, Rawstron AC, Hillmen P.

Trials. 2017 Jul 26;18(1):353. doi: 10.1186/s13063-017-2107-0.

6.

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.

Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, Vital EM.

Ann Rheum Dis. 2017 Nov;76(11):1829-1836. doi: 10.1136/annrheumdis-2017-211191. Epub 2017 Jul 6.

7.

Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study.

Rawstron AC, Ssemaganda A, de Tute R, Doughty C, Newton D, Vardi A, Evans PAS, Stamatopoulos K, Owen RG, Lightfoot T, Wakeham K, Karabarinde A, Asiki G, Newton R.

Lancet Haematol. 2017 Jul;4(7):e334-e340. doi: 10.1016/S2352-3026(16)30192-2.

9.

Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition.

Arumugakani G, Stephenson SJ, Newton DJ, Rawstron A, Emery P, Doody GM, McGonagle D, Tooze RM.

J Immunol. 2017 Jun 15;198(12):4618-4628. doi: 10.4049/jimmunol.1501761. Epub 2017 May 10.

10.

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.

Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, Hockaday A, Allsup DJ, Marshall S, Duncombe AS, O'Dwyer JL, Smith AF, Longo R, Varghese A, Hillmen P.

Leukemia. 2017 Nov;31(11):2416-2425. doi: 10.1038/leu.2017.96. Epub 2017 Mar 24.

PMID:
28336937
11.

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.

Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P.

Leukemia. 2017 Oct;31(10):2085-2093. doi: 10.1038/leu.2017.65. Epub 2017 Apr 20.

PMID:
28216660
12.

Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.

Varghese AM, Howard DR, Pocock C, Rawstron AC, Follows G, McCarthy H, Dearden C, Fegan C, Milligan D, Smith AF, Gregory W, Hillmen P; NCRI CLL Sub-Group.

Br J Haematol. 2017 Feb;176(4):573-582. doi: 10.1111/bjh.14342. Epub 2016 Dec 29.

PMID:
28032335
13.

Minimal residual disease is an independent predictor for 10-year survival in CLL.

Kwok M, Rawstron AC, Varghese A, Evans PA, O'Connor SJ, Doughty C, Newton DJ, Moreton P, Hillmen P.

Blood. 2016 Dec 15;128(24):2770-2773. Epub 2016 Oct 3.

14.

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.

Howard DR, Munir T, Hockaday A, Rawstron AC, Collett L, Oughton JB, Allsup D, Bloor A, Phillips D, Hillmen P.

Trials. 2016 Sep 20;17(1):456. doi: 10.1186/s13063-016-1581-0.

15.

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM.

JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.

16.

An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.

Worrillow L, Baskaran P, Care MA, Varghese A, Munir T, Evans PA, O'Connor SJ, Rawstron A, Hazelwood L, Tooze RM, Hillmen P, Newton DJ.

Oncogene. 2016 Oct 6;35(40):5328-5336. doi: 10.1038/onc.2016.73. Epub 2016 Apr 4.

PMID:
27041575
17.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P.

Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.

18.

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.

de Tute RM, Rawstron AC, Gregory WM, Child JA, Davies FE, Bell SE, Cook G, Szubert AJ, Drayson MT, Jackson GH, Morgan GJ, Owen RG.

Haematologica. 2016 Feb;101(2):e69-71. doi: 10.3324/haematol.2015.128215. Epub 2015 Oct 15. No abstract available.

19.

A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes.

McCarthy BA, Yancopoulos S, Tipping M, Yan XJ, Wang XP, Bennett F, Li W, Lesser M, Paul S, Boyle E, Moreno C, Catera R, Messmer BT, Cutrona G, Ferrarini M, Kolitz JE, Allen SL, Rai KR, Rawstron AC, Chiorazzi N.

Immunol Res. 2015 Dec;63(1-3):90-100. doi: 10.1007/s12026-015-8688-3.

PMID:
26318878
20.

Assessment of minimal residual disease in myeloma and the need for a consensus approach.

Rawstron AC, Paiva B, Stetler-Stevenson M.

Cytometry B Clin Cytom. 2016 Jan;90(1):21-5. doi: 10.1002/cyto.b.21272. Epub 2015 Sep 23.

21.

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.

Rawstron AC, de Tute RM, Haughton J, Owen RG.

Cytometry B Clin Cytom. 2016 Jan;90(1):54-60. doi: 10.1002/cyto.b.21271. Epub 2015 Dec 21. Review.

22.

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, Van Dongen J, Rawstron AC.

Cytometry B Clin Cytom. 2016 Jan;90(1):26-30. doi: 10.1002/cyto.b.21249. Epub 2015 Jul 6.

23.

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.

Md Yusof MY, Vital EM, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P.

Ann Rheum Dis. 2015 Sep;74(9):1734-8. doi: 10.1136/annrheumdis-2014-206496. Epub 2015 Apr 8.

PMID:
25854586
24.

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, Cook G, Jackson GH, Morgan GJ, Child JA, Owen RG.

Blood. 2015 Mar 19;125(12):1932-5. doi: 10.1182/blood-2014-07-590166. Epub 2015 Feb 2.

25.

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B.

Cytometry B Clin Cytom. 2016 Jan;90(1):31-9. doi: 10.1002/cyto.b.21228. Epub 2015 Jun 2.

26.

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.

Weinhold N, Meissner T, Johnson DC, Seckinger A, Moreaux J, Försti A, Chen B, Nickel J, Chubb D, Rawstron AC, Doughty C, Dahir NB, Begum DB, Young K, Walker BA, Hoffmann P, Nöthen MM, Davies FE, Klein B, Goldschmidt H, Morgan GJ, Houlston RS, Hose D, Hemminki K.

Haematologica. 2015 Mar;100(3):e110-3. doi: 10.3324/haematol.2014.118786. Epub 2014 Dec 5. No abstract available.

27.

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.

Landgren O, Gormley N, Turley D, Owen RG, Rawstron A, Paiva B, Barnett D, Arroz M, Wallace P, Durie B, Yuan C, Dogan A, Stetler-Stevenson M, Marti GE.

Am J Hematol. 2014 Dec;89(12):1159-60. doi: 10.1002/ajh.23831. No abstract available.

28.

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.

Hill QA, Rawstron AC, de Tute RM, Owen RG.

Blood. 2014 Aug 21;124(8):1296-9. doi: 10.1182/blood-2014-04-566521. Epub 2014 Jun 17.

29.

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S, Pocock CF.

J Clin Oncol. 2014 Apr 20;32(12):1236-41. doi: 10.1200/JCO.2013.49.6547. Epub 2014 Mar 17.

30.

Response to Dr Bredemeier's letter.

Vital EM, Dass S, Buch MH, Rawstron AC, Emery P.

Ann Rheum Dis. 2014 Jun;73(6):e34. doi: 10.1136/annrheumdis-2014-205405. Epub 2014 Mar 14. No abstract available.

PMID:
24632007
31.

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.

Weinhold N, Johnson DC, Rawstron AC, Försti A, Doughty C, Vijayakrishnan J, Broderick P, Dahir NB, Begum DB, Hosking FJ, Yong K, Walker BA, Hoffmann P, Mühleisen TW, Langer C, Dörner E, Jöckel KH, Eisele L, Nöthen MM, Hose D, Davies FE, Goldschmidt H, Morgan GJ, Hemminki K, Houlston RS.

Blood. 2014 Apr 17;123(16):2513-7; quiz 2593. doi: 10.1182/blood-2013-10-532283. Epub 2014 Jan 21.

32.

An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.

Vital EM, Dass S, Buch MH, Rawstron AC, Emery P.

Ann Rheum Dis. 2015 Jun;74(6):1195-201. doi: 10.1136/annrheumdis-2013-204544. Epub 2014 Jan 17.

PMID:
24443001
33.

Reply to M. Roschewski et al.

Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG.

J Clin Oncol. 2014 Feb 10;32(5):476-7. doi: 10.1200/JCO.2013.53.0980. Epub 2014 Jan 13. No abstract available.

PMID:
24419132
34.

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.

Ann Rheum Dis. 2014 May;73(5):909-12. doi: 10.1136/annrheumdis-2013-204417. Epub 2014 Jan 2.

PMID:
24385201
35.

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG.

J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.

PMID:
23733781
36.

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.

Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.

37.

Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL.

Vardi A, Dagklis A, Scarfò L, Jelinek D, Newton D, Bennett F, Almeida J, Rodriguez-Caballero A, Allgood S, Lanasa M, Cortelezzi A, Orlandi E, Veronese S, Montillo M, Rawstron A, Shanafelt T, Orfao A, Stamatopoulos K, Ghia P.

Blood. 2013 May 30;121(22):4521-8. doi: 10.1182/blood-2012-12-471698. Epub 2013 Apr 17.

38.

Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells.

de Tute RM, Rawstron AC, Owen RG.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):211-3. doi: 10.1016/j.clml.2013.02.018. Epub 2013 Mar 22.

PMID:
23523273
39.

Monoclonal B cell lymphocytosis--what does it really mean?

Rawstron AC.

Curr Hematol Malig Rep. 2013 Mar;8(1):52-9. doi: 10.1007/s11899-012-0144-z. Review.

PMID:
23307471
40.

Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.

Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, Chakraverty R.

Br J Haematol. 2013 Mar;160(5):640-8. doi: 10.1111/bjh.12197. Epub 2013 Jan 7.

PMID:
23293871
41.

In vitro generation of long-lived human plasma cells.

Cocco M, Stephenson S, Care MA, Newton D, Barnes NA, Davison A, Rawstron A, Westhead DR, Doody GM, Tooze RM.

J Immunol. 2012 Dec 15;189(12):5773-85. doi: 10.4049/jimmunol.1103720. Epub 2012 Nov 16.

42.

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP; VIth International Workshop on Waldenström macroglobulinaemia.

Br J Haematol. 2013 Jan;160(2):171-6. doi: 10.1111/bjh.12102. Epub 2012 Nov 15.

PMID:
23150997
43.

Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis.

Das S, Fernandez Matilla M, Dass S, Buch MH, Rawstron AC, Vital EM, Emery P.

Ann Rheum Dis. 2013 Mar;72(3):463-4. doi: 10.1136/annrheumdis-2012-202454. Epub 2012 Nov 10. No abstract available.

PMID:
23144447
44.

Clinical cytometry in Europe, 2012.

Kappelmayer J, Rawstron A, Szöllosi J, Gratama JW.

Cytometry B Clin Cytom. 2012 Nov;82(6):372-3. doi: 10.1002/cyto.b.21049. No abstract available.

45.

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P; European Research Initiative in CLL.

Leukemia. 2013 Jan;27(1):142-9. doi: 10.1038/leu.2012.216. Epub 2012 Jul 31.

PMID:
23041722
46.

FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.

Elkins K, Zheng B, Go M, Slaga D, Du C, Scales SJ, Yu SF, McBride J, de Tute R, Rawstron A, Jack AS, Ebens A, Polson AG.

Mol Cancer Ther. 2012 Oct;11(10):2222-32. doi: 10.1158/1535-7163.MCT-12-0087. Epub 2012 Jul 17.

47.

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lécrevisse Q, Lucio P, Mejstrikova E, Szczepański T, Kalina T, de Tute R, Brüggemann M, Sedek L, Cullen M, Langerak AW, Mendonça A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708).

Leukemia. 2012 Sep;26(9):1908-75. doi: 10.1038/leu.2012.120. Epub 2012 May 3.

48.

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P.

J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9.

PMID:
22493413
49.

Heterogeneity of histological transformation events in Waldenström's macroglobulinemia (WM) and related disorders.

Owen RG, Bynoe AG, Varghese A, de Tute RM, Rawstron AC.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):176-9. doi: 10.3816/CLML.2011.n.042.

PMID:
21856554
50.

Defining IgM multiple myeloma.

Owen RG, Feyler S, O'Connor SJ, Bond LR, de Tute RM, Rawstron AC.

Am J Hematol. 2011 Aug;86(8):717; author reply 718-9. doi: 10.1002/ajh.22061. No abstract available.

Supplemental Content

Loading ...
Support Center